viewImugene Ltd

Imugene has cancer vaccine trial data published in prestigious medical journal

Imugene is an Australian biotechnology company developing cancer immunotherapies, with operations in the U.S. and in Europe.

cancer cells
The company’s key assets are B-cell peptide cancer vaccines

Imugene Ltd’s (ASX:IMU) phase 1 clinical trial data for its B cell peptide cancer vaccine B-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.

The title of the article is "Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors."

The article is primarily authored by Imugene’s Scientific Advisory Board members Professor Pravin Kaumaya from the Ohio State University and Dr Tanios Bekaii-Saab from the Mayo Clinic.


Notably, this first-in-human phase 1 study evaluated the safety profile, optimal immunologic/biologic dose and immunogenicity of the combination of two peptide B-cell epitope vaccines engineered to represent the trastuzumab and pertuzumab HER-2 binding sites.

While the billion dollar blockbusters marketed by Roche/Genentech Herceptinâ and Perjetaâ have been approved for clinical use, patients often develop resistance to these therapies.

READ: Imugene targets defender B-cells with cancer vaccines HER-Vaxx and B-Vaxx

Professor Pravin Kaumaya said: “We have advanced a new paradigm in immunotherapy that focuses on humoral responses based on conformational B-cell epitope vaccines.

“The study vaccine is safe, exhibits anti-tumor activity and shows preliminary indications that peptide vaccination may avoid therapeutic resistance and offers a promising alternative to monoclonal antibody therapies.”

Two lead cancer vaccine candidates

The company’s key assets are B-lymphocyte or B-cell peptide cancer vaccines that link an immunogenic protein with a B-cell epitope peptide and include an adjuvant to induce the body into producing antibodies against normal self-proteins.

Imugene’s two lead therapeutic vaccine candidates are the HER-Vaxx vaccine and the B-Vaxx vaccine.

HER-Vaxx is an anti-HER2/neu product that has been taken through a successful phase 1b study in 14 gastric cancer patients.

B-Vaxx is also another B-cell peptide cancer vaccine and is designed to treat tumours that over-express the HER2/neu receptor.

Quick facts: Imugene Ltd

Price: 0.12 AUD

Market: ASX
Market Cap: $551.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...


Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'

Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong tells Proactive's Andrew Scott she's delighted with what the interim data has revealed in their ongoing randomised Phase 2 study of HER-Vaxx in gastric cancer. It's shown positive overall survival with a Hazard Ratio of 0.418. The median...

1 week, 1 day ago

2 min read